CELL THERAPEUTICS, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 28th, 2006 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a corporation organized under the laws of the State of Washington (the “Company”), proposes to issue to the investors listed on Schedule I (the “Investors”) of the Exchange Agreement, dated April 24, 2006, by and among the Investors and the Company (the “Exchange Agreement”) and signatory hereto, its 7.5% Convertible Senior Notes due 2011 (the “Securities”) upon the terms and subject to the conditions set forth in such Exchange Agreement. As an inducement to the Initial Purchaser to enter into the Purchase Agreement and the Investors to enter into the Exchange Agreement and in satisfaction of conditions to the obligations of the Initial Purchaser and the Investors thereunder, the Company agrees with the Initial Purchaser and the Investors for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
EXCHANGE AGREEMENT by and among CELL THERAPEUTICS, INC., and THE INVESTORS LISTED ON SCHEDULE I HERE TO dated April 24, 2006Exchange Agreement • April 28th, 2006 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
This EXCHANGE AGREEMENT, dated as of April 24, 2006 (this “Agreement”), is entered into by and between Cell Therapeutics, Inc., a Washington corporation with its principal offices located at 501 Elliott Avenue West 400, Seattle, Washington 98119 (the “Company”), and each of the entities listed on Schedule I attached hereto (each an “Existing Bondholder” and together the “Existing Bondholders”).
Cell Therapeutics, Inc. PURCHASE AGREEMENTPurchase Agreement • April 28th, 2006 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
Cell Therapeutics, Inc., a corporation organized under the laws of the State of Washington (the “Company”), hereby confirms to CRT Capital Group LLC (“CRT” or the “Initial Purchaser”), its agreement to issue and sell to CRT, as set forth below.
